WO1994021652A1 - Novel titanium compounds inhibiting tumour growth, pharmaceutical compositions containing them and process for preparing same - Google Patents
Novel titanium compounds inhibiting tumour growth, pharmaceutical compositions containing them and process for preparing same Download PDFInfo
- Publication number
- WO1994021652A1 WO1994021652A1 PCT/HU1994/000007 HU9400007W WO9421652A1 WO 1994021652 A1 WO1994021652 A1 WO 1994021652A1 HU 9400007 W HU9400007 W HU 9400007W WO 9421652 A1 WO9421652 A1 WO 9421652A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- titanium
- general formula
- stands
- group
- formula
- Prior art date
Links
- 230000004614 tumor growth Effects 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 title claims description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 150000003609 titanium compounds Chemical class 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 239000000460 chlorine Substances 0.000 claims abstract description 20
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 15
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 claims abstract description 13
- 206010062016 Immunosuppression Diseases 0.000 claims abstract description 11
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims abstract description 10
- 229950000975 salicylanilide Drugs 0.000 claims abstract description 10
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 230000008569 process Effects 0.000 claims description 23
- 239000010936 titanium Substances 0.000 claims description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 8
- QBZXQDLRICAIMA-UHFFFAOYSA-N 4-acetyl-5-methyl-2-phenyl-1h-pyrazol-3-one Chemical compound O=C1C(C(=O)C)=C(C)NN1C1=CC=CC=C1 QBZXQDLRICAIMA-UHFFFAOYSA-N 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000003467 diminishing effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 claims description 4
- 229910003074 TiCl4 Inorganic materials 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 241000011102 Thera Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 31
- 201000001441 melanoma Diseases 0.000 abstract description 16
- 230000000112 colonic effect Effects 0.000 abstract description 13
- 230000002411 adverse Effects 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- HYSIJEPDMLSIQJ-UHFFFAOYSA-N ethanolate;1-phenylbutane-1,3-dione;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)[CH-]C(=O)C1=CC=CC=C1.CC(=O)[CH-]C(=O)C1=CC=CC=C1 HYSIJEPDMLSIQJ-UHFFFAOYSA-N 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229950002361 budotitane Drugs 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- CVBUKMMMRLOKQR-UHFFFAOYSA-N 1-phenylbutane-1,3-dione Chemical compound CC(=O)CC(=O)C1=CC=CC=C1 CVBUKMMMRLOKQR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 150000004695 complexes Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003608 titanium Chemical class 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 1
- -1 5-cyclopentadienyl Chemical group 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KWOLFJPFCHCOCG-UHFFFAOYSA-N CC(c1ccccc1)=O Chemical compound CC(c1ccccc1)=O KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- MKNXBRLZBFVUPV-UHFFFAOYSA-L cyclopenta-1,3-diene;dichlorotitanium Chemical compound Cl[Ti]Cl.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 MKNXBRLZBFVUPV-UHFFFAOYSA-L 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical group C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
Definitions
- the invention relates to novel organotitanium compounds of general formula (I)
- X means chlorine or an ethoxy group when R stands for a salicylanilidato group of formula (Q)
- X 2 together means 2,3-L-ascorbate moiety when
- R stands for a benzoy lacetonato group of formula (W)
- the invention furthermore relates to a process for preparation of the above compounds and compositions.
- the compounds of general formula (I) according to the invention exert an effect diminishing immunosuppression and inhibit tumour growth. Accordingly, the invention relates also to a method of treatment which comprises administering a therapeutically effective amount of a compound of general formula (I) into the organism of a patient for diminishing immunosuppression and/or inhibiting tumour growth.
- Metal complexes represent an important class of antitumour compounds.
- a well known group of these substances are platinum-containing compounds inhibiting the tumour growth. From these, the socalled cisplatin (chemically cis-diaminedichloro- platinum of formula (II)
- the coordination number of titanium is 6 in the bis( ⁇ -diketo- nato)titanium(IV) compounds whereas it is k in the titanocenes. Presumbly, the biological consequence of this difference between the coordination numbers consists therein that, due to the different coordination geometry of the metal complexes, their interaction with the double helix of DNA is also divergent [Kovacic et al.: Anti-Cancer Drug Design 2, page 205 (1988)].
- the invention is aimed to prepare novel titanium compounds showing a more favourable and/or more selective biological activity in comparison to those known in the art.
- the invention relates to novel organotitanium compounds of general formula (I)
- X means chlorine or an ethoxy group when R
- X 2 together means 2,3-L-ascorbate group when
- the invention relates also to a process for the preparation of titanium(IV) compounds of general formula (I) wherein X means chlorine or ethoxy group when R stands for a group of formula (Q) or a group of formula (Z), the substituents being as defined abovej or X 2 together means L-2,3-ascor- bate group when R stands for a group of formula (W), which is as defined above.
- This process comprises
- salicylic acid anilide hereinafter abbreviated: salicylanilide
- ZH 1-phenyl- -3-methyl-4-acetylpyrazol-5-one
- titanium(IV) tetrachloride in an aprotic organic solvent and separating the obtained compound of general formula (I), wherein: R means (Q) and X stands for chlorine; or R means (Z) and X stands for chlorine, respectively by filtration; or
- a hydrocarbon or chlorinated aliphatic hydrocarbon preferably toluene or chloroform are used as solvents and the reaction is carried out at the boiling point of the solvent by using 2 moles of (QH) or (ZH) calculated for 1 mole of titanium tetrachloride.
- ethanol is used as solvent and reagent; and at least 2 molar equivalents of an organic base, preferably triethy lamine are employed as acid binding agent.
- titanium(IV) tetra- ethoxide or preferably titanium(IV) tetraiso- propoxide are used as titanium(IV) tetraalkoxide in a 2:1 molar ratio of (QH) or (ZH), respectively to titanium(IV) tetraalkoxide.
- the process variant d) is accomplished by using an 1:1 molar ratio of (W) 2 Ti(OC 2 H 5 ) 2 to L- -ascorbic acid.
- compositions of the invention inhibiting tumour growth and diminishing immunosuppression comprise a compound of general formula (I) together with carriers and/or auxiliaries commonly used in the drug manufacture.
- the method according to the invention for inhibiting tumour growth and diminishing immunosuppression comprises administering to a patient suffering from tumour a compound of general formula (I) together with carriers and/or auxiliaries commonly used in the therapy.
- the invention is based on the recognition that, in addition to titanocene dichloride [lchemicallybis(n 5 -cyclopentadienyl)-dichlorotitanium(IV)] and budotitane [chemically diethoxy-bis(1-phenyl- butane-1,3-dionato)titanium(IV)], the salicyl anilide-titanium complexes or diethoxy-bis(1-phenyl-3-methyl-4-acetylpyrazol-5-onato)titanium(IV) as titanium compounds also possess a significant tumour growth-inhibiting effect.
- novel titanium compounds can effectively be utilized for the treatment of tumours which are resistant to other antitumour agents.
- novel titanium compounds are more favourable than titanium derivatives known from the literature.
- the novel titanium compounds do not induce any immunosuppression.
- novel compounds proved to be particularly useful for the treatment of colonic tumours and melanoma.
- the title compound is prepared by using any of the following methods.
- Example 1 After dropwise adding 0.6 ml (0.0055 mol) of titanium tetrachloride to a solution containing 2.16 g (0.01 mole) of 1 -phenyl-3-methyl-4-acetyl- pyrazol-5-one in 20 ml of abs. toluene, the Example 1 is followed to obtain 1.8 g (65%) of dichloro-bis(1-phenyl-3-methyl-4-acetylpyrazol-5-
- C26 Colonic carcinoma of mice [C26 Colon 26 mouse-transplantable carcinoma; origin of the tumour: SRI, Birmingham, Alabama (USA); host animal: Balb/C inbred mouse; method of transplantation: subcutaneous (s.c.) implantation of tumour tissue] proved to be most sensitive since a growth inhibition of 73% was observed by using a dose of 50.0 ⁇ g/.ml.
- Table 1
- the effect inhibiting cell proliferation is shown in Table 3.
- the compound Ti-45 was most effective on COLO 205 tumour cultures since, when used in a 10 ⁇ g/ml dose, it resulted in a growth inhibition of 42%, 48 hours after the treatment. Under effect of treatment with 100.0 ⁇ g/ml of Ti-45, 97.5% of the cells were destroyed.
- the tumour spectrum of Ti-45 is different from those of titanium derivatives studied till now since its effect on HCMB melanoma cultures, which are extremely sensitive to other titanium compounds, is weaker than on colonic tumour cultures.
- An 50% inhibition of proliferation could be achieved by a dose of 50.0 ⁇ g/ml either in HCMB human melanoma cultures or C26 colonic tumour cultures.
- the effectiveness of the compound is shown thereby that, on administering 100 ⁇ g/ml of Ti-83, the tumour cultures contained altogether not more than 2.5 to 3.2% of living cells after 48 hours.
- the biological activity of the compounds according to the invention is hereinafter illustrated on transplantable tumours of mice.
- tumour growth was evaluated by the change in the life span in comparison to tumour-bearing control groups as well as by observing the size of the tumour.
- the tumour growth was determined by using a slide caliper on basis of the relation that the volume of tumour is in a direct ratio to the second power of its longest diameter. By considering this relation, the volume of the tumour was calculated by the means of the following formula:
- V cm 3 L x D 2
- V is the volume
- L is the longest diameter
- D means the shorter diameter being perpendicular to L.
- Measurements of body weight were performed from the time of treatments up to the death of the animal, daily in the first 10 days and later in every two days. Namely, a decrease of higher than 10% in body weight indicates a toxic dose of the compound used, by which the correct evaluation of antitumour effect may be disturbed.
- the compound Ti-35 exerted a significant antitumour action on 5180 mouse sarcoma in all doses tested. According to data of Table 5 the most effective dose of Ti-35 was 200 mg/kg. Beside a survival of 50%, the surviving animals became tumour-free in this dose group.
- tumour growth was delayed by 3 days on using Ti-35 in a dose of 3x100 or 200 mg/kg, respectively; and by 10 days on using a dose of 5x100 mg/kg. Under the effect of five treatments, about 50% inhibition of tumour growth was evident in comparison to the untreated control group even in the 25th day following the transplantation.
- mice bearing S180 sarcoma were sensitive only to a higher (200 mg/kg) dose of Ti-83 (see Table 7)
- the efficacy of this dose was shown by the fact that, under effect of the treatment, the death of animals began one week later and the life span of 20% of the treated animals surpassed the fourfold of the average life span of control group. Animals living over 100 days became tumour-free.
- the tumour growth-inhibiting effect exerted by a low dose of Ti-83 was observed only in the early stage of tumour growth ⁇ whereas the higher dose prolonging the survival diminished the tumour size by 40 to 50% in comparison to the control also in a later stage of tumour growth as shown in Figure 2.
- the antibody production of B lymphocytes was examined by using the immune-plaque method.
- the count of cells producing haemolytic antibodies of the spleen i.e. the count of plaque- -forming cells was determined 4 days following the immunization by using a modified variant of the direct plaque method developed by Jerne and Nordin [N. K. Jerne and A. A. Nordin: Plaque formation in agar by single antibody-producing cells, Science 140, pages 405 to 406 (1963); D. Gaal and A. No- wotny: Immune enhancement by chemotherapeutic drugs and endotoxins. Cancer Immunol, and Immunother. 6 , pages 9 to 15 (1979)].
- the suspension of splenocytes being present in the so-called active layer was used in two or three concentrations in each test group.
- the spleens of 3 animals each treated in the same manner were combined for each sample.
- the count of plaques was determined by using an electrical plaque-counting device (Titriplaque, Labor MIM). Within each sample, the plaques were parallelly counted in all cases in 3 dishes each in each dilution.
- Sheep erythrocytes washed 3 times with sterile physiological saline solution (Phylaxia, Budapest) were used as antigen.
- the sheep erythrocyte antigen was intraperitoneally (i.p.) administered in 8 x 1 doses, in 0.2 ml volume.
- Guinea pig serum (lyophilized preparation of HUMAN) diluted in 1:8 ratio was employed as complement.
- the immune response-stimulating effect of Ti-96 administered simultaneously with the immuni zation has presumably to be attributed to its inhibitory action on T-suppressor cells being firstly activated on effect of an antigen stimulus among cells playing any role in the regulation of immune response.
- the immunostimulant activity observed at Ti-96 may be favourable for the use in combinations for the compensation of immunosuppression induced by other antitumour treatments (e.g. with cytostatics or ionizing irradiation).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to novel organotitanium (IV) compounds of the general formula (R)2Ti(X)2 wherein X means chlorine or an ethoxy group when R stands for a salicylanilidato group of formula (Q) or the group of formula (Z) whereas X2 together means 2,3-L-ascorbate group when R stands for the group of formula (W). The novel substances inhibit the tumour growth, diminish the degree of immunosuppression, are useful for the treatment of resistant tumours and induce fewer adverse side effects than other organotitanium derivatives known in the art. They are particularly effective against melanoma and colonic tumours. The invention relates furthermore to the pharmaceutical compositions containing a compound of general formula (I) as active agent; as well as to the preparation of the above compounds and compositions. The compounds of general formula (I) of the invention are prepared e.g. by reacting salicylanilide (QH) or 1-phenyl-3-methyl-4-acetylpyrazolone (ZH), respectively with titanium tetrachloride in an aprotic organic solvent and separating the obtained compound of general formula (I), wherein R means (Q) or (Z), respectively and X stands for chlorine.
Description
NOVEL TITANIUM COMPOUNDS INHIBITING TUMOUR GROWTH, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME
The invention relates to novel organotitanium compounds of general formula (I)
(R)2Ti(X)2 (I) wherein
X means chlorine or an ethoxy group when R stands for a salicylanilidato group of formula (Q)
or 1-phenyl-3-methyl-4-acetylpyrazol-5- -onato group of formula (Z)
whereas
X2 together means 2,3-L-ascorbate moiety when
R stands for a benzoy lacetonato group of formula (W)
and pharmaceutical compositions containing these compounds as active agents. The invention furthermore relates to a process for preparation of the above compounds and compositions.
The compounds of general formula (I) according to the invention exert an effect diminishing immunosuppression and inhibit tumour growth. Accordingly, the invention relates also to a method of treatment which comprises administering a therapeutically effective amount of a compound of general formula (I) into the organism of a patient for diminishing immunosuppression and/or inhibiting tumour growth.
Metal complexes represent an important class of antitumour compounds. A well known group of these substances are platinum-containing compounds inhibiting the tumour growth. From these, the socalled cisplatin (chemically cis-diaminedichloro- platinum of formula (II)
Cl2Pt(NH3)2 (II) is successfully used for the chemotherapeutic treatment of tumours [Giraldi et al.: Chem. Biol. Interact. 22 , page 231 (1978)]. However, the development of drug resistance to cisplatin is rather rapid and very frequent. Thus, the research was directed to the development of metal complexes which are useful for the treatment of resistant tumours. From these antitumour metal complexes, titanium-containing substances recently got to the centre of interest. Two more important groups of antitumour titanium compounds are known: the so-called ti
tanocene compounds, i.e. bis(n5-cyclopentadienyl)- titanium(IV) compounds and bis(β-diketonato)titanium(IV) compounds. [Köpf-Maier: Cancer Chemother. Pharmacol. 23 , page 225 (1989); Keppler et al.: Arzneim. Forsch./Drug Res. 39, page 706 (1989)].
From the viewpoint of complex chemistry, there exists an important difference between the two above complex types of titanium(IV): the coordination number of titanium is 6 in the bis(β-diketo- nato)titanium(IV) compounds whereas it is k in the titanocenes. Presumbly, the biological consequence of this difference between the coordination numbers consists therein that, due to the different coordination geometry of the metal complexes, their interaction with the double helix of DNA is also divergent [Kovacic et al.: Anti-Cancer Drug Design 2, page 205 (1988)].
An additional difference between the above two types o f comp lexes l i es i n that , main l y for increasing the water-solubility of titanocenes, a number of widely varying substituents were tried beside the two cyclopentadiene groups characterizing the metalocene structure; whereas the β-diketone component was only varied in the diketonato- -titanium(IV) complexes while chlorine and ethoxy groups were retained [köpf-Maier et al.: Anti- cancer Res. 6, page 33 (1986)].
Based on literature references, β-diketonato- - t i t anium ( I V ) comp lexes proved to be mo re active [keppler et al.: Arzneim. Forsch./Drug Res. 39, page 706 (1989)] therefore, the task of this invention has been to increase the effectivity and
solubility of this type of titanium compounds by developing structural variations.
Thus, the invention is aimed to prepare novel titanium compounds showing a more favourable and/or more selective biological activity in comparison to those known in the art.
The invention relates to novel organotitanium compounds of general formula (I)
(R)2Ti(X)2 (I) wherein
X means chlorine or an ethoxy group when R
stands for the group of formula (Q)
or the group of formula (Z)
X2 together means 2,3-L-ascorbate group when
The compounds listed hereinafter are mentioned as examples of the novel compounds of general formula (I) of the invention (code numbers in parentheses):
dichloro-bis(salicylanilidato)titanium(IV) (compound Ti-35),
diethoxy-bis(salicylanilidato)titanium(IV) (compound Ti-96),
diethoxy-bis(1-phenyl-3-methyl-4-acetylpyrazol- -5-onato)titanium(IV) (compound Ti-45) and
bis(benzoylacetonato)titanium(IV) L-ascorbate (compound Ti-83).
The invention relates also to a process for the preparation of titanium(IV) compounds of general formula (I) wherein X means chlorine or ethoxy group when R stands for a group of formula (Q) or a group of formula (Z), the substituents being as defined abovej or X2 together means L-2,3-ascor- bate group when R stands for a group of formula (W), which is as defined above. This process comprises
a) reacting salicylic acid anilide (hereinafter abbreviated: salicylanilide) (QH) or 1-phenyl- -3-methyl-4-acetylpyrazol-5-one (ZH), respectively with titanium(IV) tetrachloride in an aprotic organic solvent and separating the
obtained compound of general formula (I), wherein: R means (Q) and X stands for chlorine; or R means (Z) and X stands for chlorine, respectively by filtration; or
b) reacting a compound of general formula (I), wherein R means (Q) and X stands for chlorine or R means (Z) and X stands for chlorine, respectively prepared according to process variant a), with ethanol in the presence of an acid binding agent and separating the obtained compound of general formula (I), wherein: R means (Q) and X stands for an ethoxy group; or R means (Z) and X stands for an ethoxy group, respectively by filtration: or
c) reacting salicylanilide (QH) or 1-phenyl-3- -methyl-4-acetylpyrazol-5-one (ZH), respectively with a titanium(IV) tetraalkoxide in ethanol as solvent and then separating the obtained compound of general formula (I), wherein the substituents are as defined in variant b) above, by filtration; or
d) reacting diethoxy-bis ( benzoy lacetonato) titanium(IV) of formula (W)2Ti(OC2H5)2 with L-ascorbic acid in ethanol as solvent and separating the obtained compound of general formula (I), wherein R means (W) and X2 together stands for L-ascorbate group, by evaporation of the solvent.
In process variant a) a hydrocarbon or chlorinated aliphatic hydrocarbon, preferably toluene
or chloroform are used as solvents and the reaction is carried out at the boiling point of the solvent by using 2 moles of (QH) or (ZH) calculated for 1 mole of titanium tetrachloride.
In process variant b) ethanol is used as solvent and reagent; and at least 2 molar equivalents of an organic base, preferably triethy lamine are employed as acid binding agent.
In process variant c) titanium(IV) tetra- ethoxide or preferably titanium(IV) tetraiso- propoxide are used as titanium(IV) tetraalkoxide in a 2:1 molar ratio of (QH) or (ZH), respectively to titanium(IV) tetraalkoxide.
The process variant d) is accomplished by using an 1:1 molar ratio of (W)2Ti(OC2H5)2 to L- -ascorbic acid.
The pharmaceutical compositions of the invention inhibiting tumour growth and diminishing immunosuppression comprise a compound of general formula (I) together with carriers and/or auxiliaries commonly used in the drug manufacture.
The method according to the invention for inhibiting tumour growth and diminishing immunosuppression comprises administering to a patient suffering from tumour a compound of general formula (I) together with carriers and/or auxiliaries commonly used in the therapy.
The invention is based on the recognition that, in addition to titanocene dichloride [lchemicallybis(n5-cyclopentadienyl)-dichlorotitanium(IV)] and budotitane [chemically diethoxy-bis(1-phenyl- butane-1,3-dionato)titanium(IV)], the salicyl
anilide-titanium complexes or diethoxy-bis(1-phenyl-3-methyl-4-acetylpyrazol-5-onato)titanium(IV) as titanium compounds also possess a significant tumour growth-inhibiting effect.
The main advantages of the novel compounds of general formula (I) as active agents can be summarized as follows.
- The novel titanium compounds can effectively be utilized for the treatment of tumours which are resistant to other antitumour agents.
- From the viewpoint of adverse side effects, the novel titanium compounds are more favourable than titanium derivatives known from the literature.
- In contrast to other antitumour agents, the novel titanium compounds do not induce any immunosuppression.
- The novel compounds proved to be particularly useful for the treatment of colonic tumours and melanoma.
The invention is illustrated in detail by the following non limiting Examples. It is noted that the stoichiometry of complexes was determined by elemental analysis and 1H-NMR spectroscopy.
Example 1
Dichloro-bis(salicylanilidato)titanium(IV)
Empirical formula: C26H20N2O4 Cl2Ti
Molecular weight: 544.25
The title compund is prepared by the follow-
i ng r e ac t i on :
After dropwise adding 1.8 ml (0.016 mol) of titanium tetrachloride to a solution of 6.4 g (0.03 mol) of salicylanilide in 80 ml of abs. toluene under stirring, the reaction mixture is refluxed under anhydrous conditions for 1 hour. Thereafter, gaseous hydrogen chloride remaining in the solution is blown off by bubbling dry nitrogen, the solid product formed is filtered, washed with toluene and dried in a desiccator under reduced pressure to yield 7.8 g (95%) of the title compound, m.p.: 228-230 °C (with decomposition). Analysis:
calculated: C 57.38; H 3.70; N 5.14%;
found: C 58.76; H 3.85; N 5.16%.
1H-NMR (DMS0-d6, δ ppm): ArH 6.7-8.0, m
Example 2
Diethoxy-bis(salicylanilidato)titanium(IV)
Empirical formula: C30H30N2O6Ti
Molecular weight: 562.46
The title compound is prepared by using any
of the following methods. a ) C 2 6 H 2 0 N 2 O 4 Cl2Ti C30H30N2O6Ti + 2Et
After stirring for 3 hours 0.54 g (0.001 mol) of dichloro-bis(salicylanilidato)titanium(IV) (prepared as described in Example 1) with 0.3 ml of
triethylamine in 5 ml of abs. ethanol at room temperature for 3 hours, the precipitate is filtered,
washed with ethanol and dried to give 0.35 g (62%)
of the title compound, m.p.: 260-262 °C. b)
After boiling under reflux 6.4 g (0.03 mol)
of salicylanilide with 4.5 ml (0.015 mol) of titanium(IV) tetraisopropoxide in 50 ml of abs. ethanol under anhydrous conditions for 2 hours and then
cooling down the reaction mixture, the solid precipitate is filtered and washed with ethanol to
give 6.75 g (80%) of the title compound, m.p.:
264-266 °C.
Analysis:
calculated: C 64.06; H 5.38; N 4.98%;
found: C 65.08; H 5.18; N 5.07%.
1H-NMR (DMSO-d5, δ ppm): CH3 1.03 t; CH2 3.9 q;
ArH 6.4-8.0 m.
On carrying out the reaction as described, except using titanium(IV)-tetraethoxide instead of titanium(IV) tetraisopropoxide, the product is obtained in a similar yield and purity.
Example 3
Diethoxy-bis(1-phenyl-3-methyl-4-acetyl- pyrazol-5-onato)titanium(IV)
Empirical formula: C28H32N 4 O6 Ti
Molecular weight: 568.47
The title compound is prepared by using any of the following methods.
a)
After adding 6 ml (0.02 mol) of titanium(IV) tetraisopropoxide to the solution of 8.64 g (0.04 mol) of 1-phenyl-3-methyl-4-acetylpyrazol-5- -one in 80 ml of abs. ethanol and boiling the reaction mixture under reflux for 2 hours, the precipitate formed is isolated as described in process b) of Example 2 to give the title compound in a yield of 11.0 g (96%), m.p.: 196-198 °C. [Also here, titanium(IV) tetraethoxide may be used in-
stead of the isopropoxide reagent.]
Analysis:
calculated: C 59.16; H 5,67; N 9.86%;
found: C 59.81; H 5.67; N 10.03%.
1H-NMR (CDCl3, δ ppm): CH3CH2O 1.30 t (6); 4.50 q (4);
2.35 s (6) ; CH3CO 2.50 s (6);
ArH 7.25-8.0 m (10) .
→ C28H32N4O6Ti + 2Et
diethoxy-bis(1-phenyl-3-methyl-4-acetylpyrazol-5- -onato)titanium(IV)
b/1)
After dropwise adding 0.6 ml (0.0055 mol) of titanium tetrachloride to a solution containing 2.16 g (0.01 mole) of 1 -phenyl-3-methyl-4-acetyl- pyrazol-5-one in 20 ml of abs. toluene, the Example 1 is followed to obtain 1.8 g (65%) of dichloro-bis(1-phenyl-3-methyl-4-acetylpyrazol-5-
-onato)titanium(IV), m.p, 254-255 °C (with decomposition).
b/2)
Ater stirring 1.8 g (0.003 mol) of dichloro-
-bis(1-phenyl-3-methyl-4-acetylpyrazol-5-onato)ti- tanium(IV) [prepared as described in the preceding
b/1)] with 1 ml of triethy lamine in 20 ml of abs.
ethanol at room temperature for 6 hours, the solid
precipitate is filtered, washed with ethanol and
dried to give 1.3 g (70%) of the aimed product,
m.p.: 194-196 °C.
The quality of this product is identical to
that prepared by using method a).
Example 4
bis(Benzoylacetonato)titanium(IV) L-ascorbate
Empirical formula: C26H24O10Ti
Molecular weight: 544.36
The title compound is prepared as follows:
budotitane, chemically diethoxy-bis(benzoylacetonato)titanium(IV); otherwise diethoxy-bis(1-phenylbutane-1,3-di- onato)titatium(IV)
C26H24O10Ti
bis(benzoylacetonato)titanium(IV) L-ascorbate
After boiling under reflux 6.5 g of benzoyl- acetone with 6 ml (0.02 mol) of titaπium(IV) tetraisopropoxide in 40 ml of abs. ethanol for 2 hours and then cooling down the reaction mixture, the solid precipitate is filtered and washed with ethanol to give 6.8 g (74%) of budotitane, m.p.: 126-128 °C.
After boiling under reflux 6.8 g (0.015 mol) of budotitane with 2.6 g (0.015 mol) of L-ascorbic acid in 40 ml of abs. ethanol for 3 hours, the solution obtained is evaporated to dryness in a rotavapor equipment, the residue is thoroughly triturated with abs. ether, then filtered and dried to yield 7.0 g (86%) of the aimed title compound, m.p.: 190-200 ° C (with decomposition). Analysis:
calculated: C 57.36; H 4.44%;
found: C 58.04; H 4.48%.
Notes to the above Examples:
From the starting materials used, salicylanilide and benzoylacetone are commercially available; 1-phenyl-3-methyl-4-acetylpyrazol-5-one may be prepared as described in the literature [B. S. Jensen: Acta Chem. Scand. 13 , page 1668 (195917.
The biological effects of the compounds according to the invention are illustrated in the
following non limiting Examples.
Example 5
Effect of treatment with dichloro-bis(salicylanilidato)titanium(IV) (compound Ti-35) on human melanoma and colonic tumour cultures The cells were grown (cultivated) in RPMI 1640 (Bibco) medium containing 10% of calf serum. For evaluating the antitumour effect of the compounds, the ratio of living cells to the destroyed cells was determined by using a haemo- cytometer (product of MOM). The therapeutical activity of the compounds was characterized by inhibition of the growth expressed as percentage of control.
The effect of dichloro-bis(salicylanilidato)- titanium(IV) inhibiting the cell proliferation was observed in a concentration of as low as 10 /jg/ml. In this dose range it decreases by 24 to 30% the proliferation of HCMB human melanoma cultures (Bowes human melanoma culture received from Prof. 0. Collen, Leuven, Belgium) and COLO 205 colonic tumour cultures (ATCC CCL 222) as shown in Table 1. Against this compound, C26 Colonic carcinoma of mice [C26 Colon 26 mouse-transplantable carcinoma; origin of the tumour: SRI, Birmingham, Alabama (USA); host animal: Balb/C inbred mouse; method of transplantation: subcutaneous (s.c.) implantation of tumour tissue] proved to be most sensitive since a growth inhibition of 73% was observed by using a dose of 50.0μg/.ml.
Table 1
Effect of treatment with dichloro-bis(salicylanilidato)- titanium(IV) (Ti-35) on human melanoma and colonic tumour cultures
Antitumour effect of diethoxy-bis(salicyl- anilidato)titanium(IV) (compound Ti-96) The effect of the derivative Ti-96 on human melanoma and colonic tumour cultures is summarized in Table 2. The HCMB human melanoma culture was more sensitive to the treatment with Ti-96 than human colonic tumour cultures: namely, an 50% decrease in the proliferation of melanoma cultures could be induced by 50.0 yug/ml dose of Ti-96. An. inhibition of the same degree of proliferation could be achieved only by administering a twofold dose (100.0 /ug/ml) to colonic tumour cultures (Table 2).
Table 2
Effect of treatment with diethoxy-bis(salicylanilidato)- titanium(IV) (Ti-96) on human melanoma and colonic tumour cultures
Antitumor effect of diethoxy-bis(1-phenyl-
-3-methyl-4-acetylpyrazol-5-onato)titanium(IV)
(compound Ti-45)
The effect inhibiting cell proliferation is shown in Table 3. The compound Ti-45 was most effective on COLO 205 tumour cultures since, when used in a 10 μg/ml dose, it resulted in a growth inhibition of 42%, 48 hours after the treatment. Under effect of treatment with 100.0 μg/ml of Ti-45, 97.5% of the cells were destroyed. The tumour spectrum of Ti-45 is different from those of titanium derivatives studied till now since its effect on HCMB melanoma cultures, which are extremely sensitive to other titanium compounds, is weaker than on colonic tumour cultures.
Table 3
Effect of treatment with diethoxy-bis(1-phenyl-3-methyl-4- -acetylpyrazol-5-onato)titanium(IV) (Ti-45) on human melanoma and colonic tumour cultures
Inhibitory effect of bis(benzoylacetonato)titanium(IV) L-ascorbate (compound Ti-83) on the tumour growth
The inhibitory effect of compound Ti-83 on the cell proliferation is summarized in Table 4.
An 50% inhibition of proliferation could be achieved by a dose of 50.0 μ g/ml either in HCMB human melanoma cultures or C26 colonic tumour cultures. The effectiveness of the compound is shown thereby that, on administering 100 μg/ml of Ti-83, the tumour cultures contained altogether not more than 2.5 to 3.2% of living cells after 48 hours.
Table 4
Effect of treatment with bis (benzoylacetonato)titanium(IV) L-ascorbate (Ti-83) on human melanoma and colonic tumour cultures
The biological activity of the compounds according to the invention is hereinafter illustrated on transplantable tumours of mice.
Example 9
Inhibitory effect of dichloro-bis(salicylanilidato)titanium(IV) (compound Ti-35) on the growth of 5180 mouse sarcoma
The inhibitory effect of treatments on the tumour growth was evaluated by the change in the life span in comparison to tumour-bearing control groups as well as by observing the size of the tumour. The tumour growth was determined by using a slide caliper on basis of the relation that the volume of tumour is in a direct ratio to the second power of its longest diameter. By considering this relation, the volume of the tumour was calculated by the means of the following formula:
V cm3 = L x D2
wherein: V is the volume;
L is the longest diameter; and
D means the shorter diameter being perpendicular to L.
Measurements of body weight were performed from the time of treatments up to the death of the animal, daily in the first 10 days and later in every two days. Namely, a decrease of higher than 10% in body weight indicates a toxic dose of the compound used, by which the correct evaluation of antitumour effect may be disturbed.
The compound Ti-35 exerted a significant antitumour action on 5180 mouse sarcoma in all doses tested. According to data of Table 5 the most effective dose of Ti-35 was 200 mg/kg. Beside a survival of 50%, the surviving animals became tumour-free in this dose group.
In addition to the data of survival, the effectivity of the compound was proven by the data of Figure 1 illustrating the effect of Ti-35 used in various doses and treatment rates on 5180 tumour growth.
The development of a measurable tumour was delayed by 3 days on using Ti-35 in a dose of 3x100 or 200 mg/kg, respectively; and by 10 days on using a dose of 5x100 mg/kg. Under the effect of five treatments, about 50% inhibition of tumour growth was evident in comparison to the untreated control group even in the 25th day following the transplantation.
Example 10
Effect of diethoxy-bis(1-phenyl-3-methyl-4- -acetylpyrazol-5-onato)titanium(IV) (compound Ti-45) on the B16 mouse melanoma
In the case of B16 transplantable melanoma mouse tumour [k arolinska Inst. , Stockholm; host animal: BDF1 hybride mouse, first generation of the crossing of C57 Black female mice with DBA male mice; the transplantation was carried out by using subcutaneous tumour tissue]. The life span of tumour-bearing animals was prolonged by increasing the dose of Ti-45 (as shown in Table 6) . An increase of nearly 60% in the life span was achieved by using Ti-45 in a dose of 80 mg/kg.
Table 6
Effect of diethoxy-bis(1-phenyl-3-methyl-4-acetyl- pyrazol-5-onato)titanium(IV) (Ti-45) on the survival of mice bearing B16 melanoma
* Treatments were begun 2 days following the tumour transplantation
q2d: Repetitions in every 2 days
E xampl e 1 1
The antitumour effect of bis (benzoylacetonato)titanium(IV) L-ascorbate (compound Ti-83) on the S180 mouse sarcoma
Mice bearing S180 sarcoma were sensitive only to a higher (200 mg/kg) dose of Ti-83 (see Table 7) The efficacy of this dose was shown by the fact that, under effect of the treatment, the death of animals began one week later and the life span of 20% of the treated animals surpassed the fourfold of the average life span of control group. Animals living over 100 days became tumour-free. The tumour growth-inhibiting effect exerted by a low dose of Ti-83 was observed only in the early stage of tumour growth^ whereas the higher dose prolonging the survival diminished the tumour size by 40 to 50% in comparison to the control also in a later stage of tumour growth as shown in Figure 2.
Example 12
Antitumour effect of diethoxy-bis(salicylanilidato)titanium(IV) (compound Ti-96) on the S180 mouse sarcoma
The effect of Ti-96 on the survival of mice bearing S180 sarcoma is shown by the data of
Table 8.
Table 8
Effect of diethoxy-bis(salicylanilidato)titanium(IV) (Ti-96) on the survival of mice bearing S180 sarcoma
* Treatments were begun 2 days following the tumour transplantation
q2d: Repetitions in every 2 days
Concerning the survival, nearly no difference was found between the effects of both doses. A survival over 80 days and, in the cases of surviving animals, the remission of tumour were observed on 40% or 20%, respectively of the treated groups. Both doses (100 or 200 mg/kg) caused nearly 50% inhibition of the tumour growth in comparison to the control. A daily repeated dose of 4 x 100 mg/kg delayed the appearance of a tumour of measurable size by 4 days.
Example 13
Effect of titanium compounds on the immune system
The adverse side effect of antitumour cytostatics on the immune system, i.e. the immunosuppression is commonly known. Starting from this fact, the influence of the effective antitumour, salicylic-containing dichloro-bis(salicylanilidato)- titanium(IV) (compound Ti-35) and diethoxy-bis(salicylanilidato)titanium(IV) (compound Ti-96) on the humoral immune response of BDF mice to the antigen was investigated.
The antibody production of B lymphocytes was examined by using the immune-plaque method.
The count of cells producing haemolytic antibodies of the spleen, i.e. the count of plaque- -forming cells was determined 4 days following the immunization by using a modified variant of the direct plaque method developed by Jerne and Nordin [N. K. Jerne and A. A. Nordin: Plaque formation in agar by single antibody-producing cells, Science 140, pages 405 to 406 (1963); D. Gaal and A. No-
wotny: Immune enhancement by chemotherapeutic drugs and endotoxins. Cancer Immunol, and Immunother. 6 , pages 9 to 15 (1979)].
The suspension of splenocytes being present in the so-called active layer was used in two or three concentrations in each test group. The spleens of 3 animals each treated in the same manner were combined for each sample. The count of plaques was determined by using an electrical plaque-counting device (Titriplaque, Labor MIM). Within each sample, the plaques were parallelly counted in all cases in 3 dishes each in each dilution.
Sheep erythrocytes washed 3 times with sterile physiological saline solution (Phylaxia, Budapest) were used as antigen. The sheep erythrocyte antigen was intraperitoneally (i.p.) administered in 8 x 1 doses, in 0.2 ml volume. Guinea pig serum (lyophilized preparation of HUMAN) diluted in 1:8 ratio was employed as complement.
The results obtained by intraperitoneal treatments used in two doses and in two different times related to the time of immunization are shown in Table 9. None of the doses of Ti-35 or Ti-96, respectively administered 24 hours before immunization influenced the antibody production of B lymphocytes against the antigen. Contrarily, when employed simultaneously with the immunization, both doses of Ti-96 significantly stimulated the humoral immune response of BDF,. mice.
The immune response-stimulating effect of Ti-96 administered simultaneously with the immuni
zation has presumably to be attributed to its inhibitory action on T-suppressor cells being firstly activated on effect of an antigen stimulus among cells playing any role in the regulation of immune response.
In our opinion, it is important in the cases of Ti-35 and Ti-96 that, in opposition to other known cytostatics used in the clinical practice, no immunosuppressi ve side effect adversely affecting the therapeutical activity has to be considered.
The immunostimulant activity observed at Ti-96 may be favourable for the use in combinations for the compensation of immunosuppression induced by other antitumour treatments (e.g. with cytostatics or ionizing irradiation).
Table 9
Influence of dichloro-bis(salicylanilidato) titanium(IV) (Ti-35) and diethoxy-bis(salicylanilidato)- titanium(IV) (Ti-96) on the humoral immune response of BDF1 mice
*
Group treated (immunized) only by sheep erythrocyte antigen
**
PFC: plaque-forming cell test
Claims
1. Novel organotitanium compounds of general formula (I)
(R)2Ti(X)2 (I) wherein
X means chlorine or an ethoxy group when R stands for the group of formula (Q)
X2 together means 2,3-L-ascorbate group when R stands for the group of formula (W)
2. Pharmaceutical composition inhibiting tumour growth and inducing a lower degree of immunosuppression, which c o m p r i s e s as active ingredient a therapeutically effective amount of a compound of general formula (I), wherein the substituents are as defined in claim 1, in admixture with carriers and/or auxiliaries commonly used in the drug manufacture.
3. Process for the preparation of the organo- titanium(IV) compounds of general formula (I), wherein the substituents are as defined in claim 1, which c o m p r i s e s
a) reacting salicylic acid anilide (hereinafter abbreviated: salicylanilide)(QH) or 1-phenyl- -3-methyl-4-acetylpyrazol-5-one (ZH), respectively with titanium(IV) tetrachloride in an aprotic organic solvent and separating the obtained compound of general formula (I), wherein: R means (Q) and X stands for chlorine; or R means (Z) and X stands for chlorine, respectively by filtration; or
b) reacting a compound of general formula (I), wherein R means (Q) and X stands for chlorine or R means (Z) and X stands for chlorine, respectively prepared according to process variant a), with ethanol in the presence of an acid binding agent and separating the obtained compound of general formula (I), wherein: R means (Q) and X stands for an ethoxy group; or R means (Z) and X stands for an ethoxy group, respectively by filtration; or c) reacting salicylanilide (QH) or 1-phenyl-3- -methyl-4-acetylpyrazol-5-one (ZH), respectively with a titanium(IV) tetraalkoxide in ethanol as solvent and then separating the obtained compound of general formula (I), wherein the substituents are as defined in variant b) above, by filtration; or
d) reacting diethoxy-bis(benzoylacetonato)titanium(IV) of formula (W) 2Ti(OC2H5)2 with L-ascorbic acid in ethanol as solvent and separating the obtained compound of general formula (I), wherein R means (W) and X2 together stands for L-ascorbate group, by evaporation of the solvent.
4. A process as claimed in claim 3, which c o m p r i s e s carrying out the reaction in all process variants in an anhydrous solvent at a temperature between 25 °C and 110 °C.
5. A process as claimed in claim 3 or claim 4, which c o m p r i s e s using in process variant a) the same hydrocarbon or chlorinated aliphatic hydrocarbon, preferably toluene or chloroform as solvent and carrying out the reaction at the boiling point of the solvent by using a 2:1 molar ratio of (QH or ZH) : TiCl4.
6. A process as claimed in claim 3 or claim 4, which c o m p r i s e s using in process variant b) ethanol as solvent and reagent and at least 2 molar equivalents of an organic base, preferably triethylamine as acid binding agent.
7. A process as claimed in claim 3 or claim 4, which c o m p r i s e s using in process variant c) titanium(IV) tetraethoxide or preferably titanium(IV) tetraisopropoxide as titanium(IV) tetraalkoxide in a 2:1 molar ratio of (QH) or (ZH), respectively to titanium(IV) tetraalkoxide.
8. A process as claimed in claim 3 or claim 4, which c o m p r i s e s carrying out the reaction of process variant d) with an 1:1 molar ratio of (W)2Ti (OC2H5)2:L-ascorbic acid.
9. A process for the preparation of a pharmaceutical composition inhibiting tumour growth and inducing an immunosuppression of lower degree, which c o m p r i s e s mixing as active ingredient a therapeutically effective amount of a compound of general formula (I), wherein the substituents are as defined in claim 1, prepared by using any of the process variants a) to d) of claim 3 with carriers and/or auxiliaries commonly used in the drug manufacture.
10. Method for inhibiting tumour growth as well as diminishing immunosuppression/ c h a r a c t e r i z e d by administering to a patient to be treated (in the need of such treatment) a thera peutically effective amount of a compound of general formula (I), wherein the substituents are as defined in claim 1, alone or in the form of a pharmaceutical composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP9300789 | 1993-03-19 | ||
HU9300789A HU212105B (en) | 1993-03-19 | 1993-03-19 | Process for producing titanium compounds of antitumor activiti and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994021652A1 true WO1994021652A1 (en) | 1994-09-29 |
Family
ID=10983373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU1994/000007 WO1994021652A1 (en) | 1993-03-19 | 1994-03-18 | Novel titanium compounds inhibiting tumour growth, pharmaceutical compositions containing them and process for preparing same |
Country Status (2)
Country | Link |
---|---|
HU (1) | HU212105B (en) |
WO (1) | WO1994021652A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3518447A1 (en) * | 1985-05-22 | 1986-11-27 | Hartmut Prof. Dr. 1000 Berlin Köpf | TITANOCEN COMPLEXES AND THEIR USE AS CYTOSTATICA IN CANCER FIGHTING |
AU7605187A (en) * | 1987-07-23 | 1989-01-27 | Kerteszet I Es Elelmiszer Ipari Egyetem | Method for improving and increasing the multiplication biological properties and power of resistance against pathogens of living creatures-such as domestic animals and plants-and for favourable control of physiological process |
WO1990006749A1 (en) * | 1980-10-04 | 1990-06-28 | Keller Heimo J | Metal complexes having an antineoplastic action, and medicaments containing these complexes |
DE3923270A1 (en) * | 1989-07-14 | 1991-01-17 | Medac Klinische Spezialpraep | WATER-SOLUBLE PHARMACEUTICAL METALLOCEN COMPLEX COMPOSITION |
DD289275A5 (en) * | 1989-11-20 | 1991-04-25 | Paedagogische Hochschule "N.K.Krupskaja",De | PROCESS FOR PRODUCING NEW TITANOCENCHELATE COMPOUNDS |
-
1993
- 1993-03-19 HU HU9300789A patent/HU212105B/en not_active IP Right Cessation
-
1994
- 1994-03-18 WO PCT/HU1994/000007 patent/WO1994021652A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006749A1 (en) * | 1980-10-04 | 1990-06-28 | Keller Heimo J | Metal complexes having an antineoplastic action, and medicaments containing these complexes |
DE3518447A1 (en) * | 1985-05-22 | 1986-11-27 | Hartmut Prof. Dr. 1000 Berlin Köpf | TITANOCEN COMPLEXES AND THEIR USE AS CYTOSTATICA IN CANCER FIGHTING |
AU7605187A (en) * | 1987-07-23 | 1989-01-27 | Kerteszet I Es Elelmiszer Ipari Egyetem | Method for improving and increasing the multiplication biological properties and power of resistance against pathogens of living creatures-such as domestic animals and plants-and for favourable control of physiological process |
DE3923270A1 (en) * | 1989-07-14 | 1991-01-17 | Medac Klinische Spezialpraep | WATER-SOLUBLE PHARMACEUTICAL METALLOCEN COMPLEX COMPOSITION |
DD289275A5 (en) * | 1989-11-20 | 1991-04-25 | Paedagogische Hochschule "N.K.Krupskaja",De | PROCESS FOR PRODUCING NEW TITANOCENCHELATE COMPOUNDS |
Also Published As
Publication number | Publication date |
---|---|
HUT66457A (en) | 1994-11-28 |
HU9300789D0 (en) | 1993-06-28 |
HU212105B (en) | 1996-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI72321B (en) | FOER FARING FRAMSTAELLNING AV NYA VID BEHANDLING AV CANCER ANVAENDBARA PLATINA (IV) -DIAMINKOMPLEXER | |
EP0155705B1 (en) | Antitumor platinum complexes | |
KR100484504B1 (en) | Inclusion compound comprising curcurbituril derivatives as host molecule and pharmaceutical composition comprising the same | |
JP3697210B2 (en) | Anti-tumor derivative of double dicarboxylic acid diaminoplatin complex, preparation method thereof, pharmaceutical composition containing the same and application method of the derivative | |
AU682105B2 (en) | Trinuclear cationic platinum complexes having antitumour activity and pharmaceutical compositions containing them | |
CN102731580B (en) | Binuclear platinum (II)-diphosphonic acid coordination compound, preparation method and application thereof | |
Hadi et al. | The Potency Study of Organotin (IV) 3-Nitrobenzoate Compounds as Antimalarial Agents | |
Al‐Allaf et al. | Organotin (IV) complexes with various donor ligands and their cytotoxicity against tumour cell lines. Part (I): R2SnCl2 with Schiff bases; unusual C N bond cleavage of the bases and X‐ray structures of the ionic products formed | |
Gielen et al. | Synthesis, characterization and in vitro antitumour activity of novel organotin derivatives of 1, 2-and 1, 7-Dicarba-Closo-dodecaboranes | |
EA015619B1 (en) | Bis-platinum complexes with antitumor activity | |
EP0176005B1 (en) | Novel platinum complexes | |
EP0163316A1 (en) | Platinum-intercalative complexes for the treatment of cancer | |
US5028727A (en) | Platinum-(IV)-diamine complex | |
CN105481902B (en) | Platinum (IV) anticancer compound using dihydrogen phosphate as axial ligand | |
JPH024797A (en) | Platinum ligand compound | |
US4291027A (en) | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes | |
WO1994021652A1 (en) | Novel titanium compounds inhibiting tumour growth, pharmaceutical compositions containing them and process for preparing same | |
CN113549122B (en) | Glycosylated tetravalent platinum compound targeting GLUTs, synthetic method and application thereof | |
EP0232785B1 (en) | Hydroxylated 1,2-diaminocyclohexane platinum complexes | |
EP0793667A1 (en) | Trinuclear cationic platinum complexes having antitumour activity and pharmaceutical compositions containing them | |
JPH02108694A (en) | Platinum (ii) diamine complex | |
JPS61249993A (en) | Novel organoplatinum complex and production thereof | |
AU597932B2 (en) | (Gem-heterocyclodimethanamine-N,N') platinum complexes | |
NO172184B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF MEDICINALLY EFFECTIVE PLATINA COMPLEXS WITH ANTI-TUMULOUS EFFECT | |
CA1256115A (en) | Platinum complexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |